Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
emnergize: Empasiprubart IV in Adults With Chronic Inflammatory Demyelinating Polyneuropathy
jRCT2021250030Phase 3Recruiting
- Sponsor
- argenx
- Start
- Feb 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, double-blind trial of empasiprubart in chronic inflammatory demyelinating polyneuropathy (CIDP) (3 arms), sponsored by argenx. Primary endpoint: Adjusted INCAT improvement at week 24. Started Feb 2026; status: recruiting.
02
Drugs
empasiprubart
03
Conditions
chronic inflammatory demyelinating polyneuropathy (CIDP)
Beyond the preview
Go deeper on jRCT2021250030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2021250030.